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Introduction: Minimal residual disease is an important independent prognostic factor that
can  identify poor responders among patients with acute lymphoblastic leukemia.
Objective: The aim of this study was to analyze minimal residual disease using immunoglob-
ulin  (Ig) and T-cell receptor (TCR) gene rearrangements by conventional polymerase chain
reaction followed by homo-heteroduplex analysis and to compare this with real-time
polymerase chain reaction at the end of the induction period in children with acute lym-
phoblastic leukemia.
Methods: Seventy-four patients diagnosed with acute lymphoblastic leukemia were enrolled.
Minimal residual disease was evaluated by qualitative polymerase chain reaction in 57 and
by  both tests in 44. The Kaplan–Meier and multivariate Cox methods and the log-rank test
were used for statistical analysis.
Results: Nine patients (15.8%) were positive for minimal residual disease by qualitative poly-
merase chain reaction and 11 (25%) by real-time polymerase chain reaction considering a
cut-off point of 1 × 10−3 for precursor B-cell acute lymphoblastic leukemia and 1 × 10−2 for
T-cell acute lymphoblastic leukemia. Using the qualitative method, the 3.5-year leukemia-
free  survival was signiﬁcantly higher in children negative for minimal residual disease
compared to those with positive results (84.1% ± 5.6% versus 41.7% ± 17.3%, respectively;
p-value = 0.004). There was no signiﬁcant association between leukemia-free survival and
minimal residual disease by real-time polymerase chain reaction. Minimal residual disease
by  qualitative polymerase chain reaction was the only variable signiﬁcantly correlated to
leukemia-free survival.
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Conclusion: Given the difﬁculties in the implementation of minimal residual disease mon-
itoring by real-time polymerase chain reaction in most treatment centers in Brazil, the
qualitative polymerase chain reaction strategy may be a cost-effective alternative.
©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by
Elsevier Editora Ltda. All rights reserved.Introduction
With current cure rates of 80–85%, modern treatment proto-
cols for acute lymphoblastic leukemia (ALL) incorporate risk
stratiﬁcation of patients, in order to intensify treatment in
higher-risk patients and reduce adverse effects of those with
greater probability of cure.1
Several studies have shown that the detection of resid-
ual leukemic cells, that is minimal residual disease (MRD),
especially at the end of the induction period, is an impor-
tant prognostic factor to identify patients with higher risk of
relapse.2–4
Current ALL protocols use immunophenotyping by ﬂow
cytometry or real-time quantitative polymerase chain reaction
(RQ-PCR) to evaluate MRD.  Both methods are highly sensitive
and speciﬁc but complex and expensive.5,6
The evaluation of MRD  by ﬂow cytometry is a fast quan-
titative method that requires limited sample manipulation
and may reach sensitivities of 10−3 to 10−5 depending on
the number of ﬂuorochromes used in the analysis (from 3
to 9).6 However, the expression of antigens may vary during
treatment and normal B precursor cells may express markers
similar to those of lymphoblasts in ALL.7
Clonal immunoglobulin (Ig)  and T cell receptor (TCR) gene
rearrangements have been widely used in MRD evaluation
because of their high frequencies in both B-ALL and T-cell
acute lymphoblastic leukemia (T-ALL) cells.8 RQ-PCR analy-
sis of rearranged Ig and TCR genes has high sensitivity (10−4
to 10−5), a good degree of standardization, besides the advan-
tage of using a stable sample (DNA). On the other hand, the
high cost and complexity may hinder its implementation in
most oncohematology units in developing countries.6
MRD  analysis of Ig and TCR gene rearrangements can
also be accomplished by qualitative PCR followed by homo-
heteroduplex analysis to discriminate clonal PCR amplicons,
a much simpler method. Although less sensitive (10−2 to 10−3),
the test can be used to identify patients at higher risk of
relapse.9
Objective
This study aimed to compare MRD  results of qualitative PCR
and the gold standard, RQ-PCR.
Methods
PatientsSeventy-four consecutive zero- to 19-year-old patients
with a diagnosis of ALL were investigated. Patients wereidentiﬁed in three leading institutions in Belo Horizonte,
Minas Gerais, Brazil: Hospital das Clínicas da Universi-
dade Federal de Minas Gerais (UFMG) (n = 52); Hospital da
Baleia/Fundac¸ão Benjamin Guimarães (n = 14); and Santa Casa
de Misericórdia de Belo Horizonte (n = 8). Bone marrow sam-
ples were collected from January 2010 to December 2012.
Most patients (n = 45) were treated according to the Grupo
Brasileiro de Tratamento da Leucemia Infantil-leucemia lin-
foide aguda (GBTLI-LLA-99) protocol although 21 patients were
treated according to GBTLI-LLA-2009, and eight patients using
the Associazione Italiana Ematologia ed Oncologia Pediatrica
(AIEOP-95) protocol. According to the GBTLI-LLA-99 and 2009
protocols, patients older than nine years at diagnosis and/or
with a white blood cell (WBC) count above 50 × 109/L were
assigned to the group with high risk of relapse and the others
were assigned to the low-risk group and received less intensive
treatment. Approval was obtained from the Ethics Committee
of the three participating institutions and all guardians and/or
patients gave their informed written consent to participate in
the study according to the Declaration of Helsinki. No family
or patient refused to sign the informed consent form.
Diagnostic  studies
Diagnosis of ALL was made by standard morphological anal-
ysis and by ﬂow cytometry immunophenotyping. Karyotype
analysis and reverse transcription PCR (RT-PCR) were also per-
formed at diagnosis for the BCR-ABL, TCF3/PBX1, ETV6/RUNX1
and MLL-AF4 fusion genes.
Cell  samples  and  DNA  isolation
Bone marrow samples were obtained from the patients at
diagnosis (Day 0) and at the end of the induction period (Day
28 for those treated according to GBTLI-LLA-99 protocol; Day
33 for AIEOP-95; and Day 35 for GBTLI-LLA-2009).
Mononuclear cells were separated using Histopaque®
(Sigma–Aldrich, Saint Louis, USA) centrifugation gradient
and DNA was extracted with the NucleoSpin® Tissue Kit
(Macherey-Nagel, Düren, Germany) according to manufac-
turer’s instructions. The extracted DNA was quantiﬁed using
the NanoDrop 2000TM Spectrophotometer. The quality of DNA
was conﬁrmed through ampliﬁcation of the Fms-like tyrosine
kinase 3 (FLT3) gene, according to Meshinchi et al.10
Identiﬁcation  of  immunoglobulin/T  cell  receptor  minimal
residual  disease  targets  at  diagnosisDNA from diagnostic samples was screened using 19 primer
mixes according to the ALL subtype. For precursor B-cell
acute lymphoblastic leukemia (pB-ALL), BIOMED2 primer sets
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or the complete and incomplete IgH (VH-(DH)-JH, DH-JH),
gK (Vk-Kde, Intron-Kde), TCRG (Vg-Jg1.3/2.3 + Jg1.1/2.1) and
ncomplete TCRD gene rearrangements (Vd2-Dd3, Dd2-Dd3)
ere used.11 For T-ALL, BIOMED2 primer sets for the IgH (DH-
H), TCRG (Vg-Jg1.3/2.3 + Jg1.1/2.1), TCRD (Vd-(Dd)-Jd1, Dd2-Jd1,
d2-Dd3, Dd2-Dd3) gene rearrangements and for the Sil-Tal
Sil-Tal1, Sil-Tal2) microdeletion were used.11,12
PCR was carried out in 25 L reactions containing 25 ng of
NA, 1 U of Tth DNA polymerase (Biotools, Madrid, Spain),
0 pmol of each primer, 2 mM of MgCl2, and 100 M of each
NTP. The PCR ampliﬁcation cycles have been previously
escribed.11,12 Two negative controls were used in each PCR
ssay: one without DNA and the other containing pools of
olyclonal DNA obtained from peripheral blood mononuclear
ells (PBL) from ten healthy donors. PCR products were ana-
yzed by homo-heteroduplex analysis on 12% acrylamide gels
tained with Sybr Safe DNA gel stain (Invitrogen, USA), as
reviously described.13 Ampliﬁed gene rearrangements were
haracterized as clonal when a band of the expected size was
isible,11 and not present in the PBL control. The band contain-
ng the clonal amplicon, according to the expected molecular
ize, was cut from the gel, dissolved in water and stored at
20 ◦C for subsequent sequencing.
ualitative  minimal  residual  disease  analysis
or MRD  monitoring by the qualitative method, at least two
lonal markers identiﬁed at diagnosis were tested, whenever
ossible. PCRs and homo-heteroduplex analyses were car-
ied out as described above, except that 500 ng of DNA were
sed. Day 28–35 samples, diagnostic DNA samples, as well as
he polyclonal PBL DNA and the non-template controls were
un in parallel. Follow-up samples were considered positive
hen they showed the same migration pattern and molecular
eight as the samples at diagnosis.
equencing  and  design  of  patient-speciﬁc  primers
lonal PCR products from Day 0 that had been dissolved
n water were re-ampliﬁed in a volume of 50 L using the
ame primer sets (but with T7 or M13  extensions) and reac-
ion conditions as described above. Sequencing reactions
ere carried out using the BigDye Terminator Cycle Sequenc-
ng Reaction Kit (PE Applied Biosystems) and T7 and M13
rimers. Sequences were run using the ABI Prism 3130 Genetic
nalyzer (PE Applied Biosystems) and analyzed using the
hromas Lite 2.4 software (Technelysium Pty Ltd.). Patient-
peciﬁc junctional region sequences were identiﬁed with the
last tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and IMGT/V-
UEST (http://www.imgt.org/IMGT vquest/share/textes/).
The Primer3 Biotools software (http://biotools.umassmed.
du/bioapps/primer3 www.cgi) was used to design patient-
peciﬁc primers complementary to the junctional region
equence and compatible with primers and probes previ-
usly described for IgH,14 IgK,15 TCRG,16 TCRD,17 and Sil-Tal.18
wo patient-speciﬁc primers were designed for each Ig/TCR
egion. GC rich (>80%) junctional regions were not used as
argets.
Patient-speciﬁc primers were tested for speciﬁcity and sen-
itivity. RQ-PCR analysis was performed in duplicate, in a ﬁnal 1 5;3  7(6):373–380 375
volume of 25 L containing 100 ng of DNA, 5 M sequence-
speciﬁc TaqMan probes (Applied Biosystems), 7.5 pmol of
each primer, and TaqMan Universal Master mix  (2×) (Applied
Biosystems), on the StepOnePlusTM RQ-PCR System (Applied
Biosystems). Results were analyzed with the StepOne soft-
ware v2.3 and the sensitivity was deﬁned as the point with
the greatest dilution in which the cycle threshold (Ct) reached
at least one Ct below the lowest Ct for polyclonal PBL. The
primer was considered more  speciﬁc the greater the difference
between the sensitivity of Ct and that of PBL Ct.
Minimal  residual  disease  using  real-time  polymerase
chain  reaction
RQ-PCR MRD analysis of Day 28–35 samples was performed
and interpreted according to the guidelines of van der Velden
et al.19 RQ-PCRs were carried out as described above for sen-
sitivity tests, except that 500 ng of DNA were used. Results
were normalized using N-RAS as a control gene.18 MRD  cut-
off points were deﬁned according to the GBTLI-2009 protocol,
in which patients with results above 1 × 10−3 for pB-ALL and
1 × 10−2 for T-ALL are considered positive and classiﬁed as
poor responders at the end of the induction therapy.
Statistical  analysis
Overall survival (OS), event-free survival (EFS) and leukemia-
free survival (LFS) curves were plotted employing the
Kaplan–Meier method. The OS was calculated from the date of
diagnosis to the date of death or last follow-up. The EFS was
calculated from the date of diagnosis to the date of relapse
or death. The LFS was calculated from the date of leukemia
remission to the date of relapse (patients who died in remis-
sion was censored on the date of death). The cut-off date for
censoring non-relapsed patients was 22 October 2014. Curves
for different MRD groups were compared by the log-rank test
according to age, WBC  count at diagnosis, immunopheno-
type, risk group, gender, institution of origin and treatment
protocol. All statistical analyses were performed using the
Statistical Program for the Social Sciences (SPSS) software (ver-
sion 20.0) with the level of signiﬁcance set for p-values ≤ 0.05.
The association between LFS, qualitative MRD  and RQ-
PCR MRD results were adjusted for the effect of clinical
and biological categorical variables in a multivariate Cox
model.
Results
The main clinical and biological characteristics of patients at
diagnosis and in the induction phase are depicted in Table 1.
Fourteen out of the 74 patients were not tested for gene
rearrangements because there was not enough bone marrow
material for molecular biology studies at diagnosis, and two
patients died during the induction period. Thus, 58 patients
were screened for Ig/TCR rearrangements. At least one clonal
marker was detected in 57 children (98.3%): 47 out of 47 (100%)
for pB-ALL and 10 out of 11 (90.9%) for T-ALL. Two or more
clonal markers were detected in 46 children (79.3%): 41 out of
47 (87.2%) for pB-ALL and 5 out of 11 (45.5%) for T-ALL. Ig/TCR
376  rev bras hematol hemoter.
Table 1 – Clinical and biological variables of children
with acute lymphoblastic leukemia (n = 74).
Variable n  (%)
Gender (n = 74)
Male 38 (51.4)
Female 36 (48.6)
Age (n = 74)
≤1 year 0
1–9 years 45 (60.8)
≥9 years 29 (39.2)
Immunophenotype (n = 74)
Precursor B-lineage 60 (81.1)
T-lineage 14 (18.9)
CNS status at diagnosis (n = 70)
CNS 1 70 (100)
CNS 2 or 3 0
Initial risk group (n = 74)
Low risk 28 (37.8)
High risk 46 (62.2)
White blood cell count at diagnosis (n = 74)
<50 × 109/L 57 (77)
≥50 × 109/L 17 (23)
BCR/ABL or MLL/AF4 gene fusion (n = 68)
Positive 5 (7.4)
Negative 63 (92.6)
Event during induction phase (n = 74)
Complete remission 72 (97.3)
Death during induction 2 (2.7)CNS: central nervous system.
rearrangements were not be detected in one patient with T-
ALL.
The most frequent rearrangement for pB-ALL was IgH
(74.5%), followed by TCRD (59.6%), IgK (53.2%) and TCRG (38.3%).
For T-ALL, the most frequent rearrangement was TCRG (90.9%),
followed by Sil-Tal1 (18.2%).
Of the 57 patients with at least one clonal marker, 51
(89.5%) had suitable targets for the design of speciﬁc primers.
A total of 173 primers (75 for IgH, 43 for TCRD, 33 for TCRG
and 22 for IgK)  were designed and tested for sensitivity and
Table 2 – Comparative analysis of minimal residual disease by 
real-time quantitative polymerase chain reaction (RQ-PCR).
RQ-PCR 
Neg
pB-ALL (n = 39)
>1 × 10−2 4 
>1 × 10−3 and ≤1 × 10−2 6 
<1 × 10−3a 29 2
T-ALL (n = 5)
>1 × 10−2a 1 
>1 × 10−3 and ≤1 × 10−2 1 
<1 × 10−3 3 
pB-ALL: precursor-B cell acute lymphoblastic leukemia; T-ALL: T-cell acute
a Cut-off points established by GBTLI-2009 protocol: 1 × 10−3 for pB-ALL; 1 2 0 1 5;3  7(6):373–380
speciﬁcity. Primers for the Sil-Tal1 rearrangement were also
tested in two patients. IgH, IgK and Sil-Tal1 primers achieved
higher sensitivity (1 × 10−4) than primers for TCRG and TCRD.
A high proportion of TCRG and TCRD primers were unspeciﬁc
(66.7% and 55.8%, respectively). After testing the 175 primers,
44 patients had at least one primer that was suitable for RQ-
PCR monitoring of MRD.
MRD  evaluation
At the end of the induction therapy, 9/57 patients (15.8%) had
positive MRD  by the qualitative assay, 12.8% (6/47) for pB-ALL
and 30% (3/10) for T-ALL. Eight out of the nine MRD-positive
patients had been assigned to the high-risk group at diagnosis;
one of them was BCR-ABL-positive and another was MLL-AF4-
positive. Sensitivity of the assay with the qualitative primers
was 10−2 to 10−3.13
MRD analysis by RQ-PCR was performed in 14/44 (32%)
patients using two markers and in 30 (68%) using just one
marker. Twenty-seven IgH, 12 IgK, ﬁve TCRG and 11 TCRD rear-
rangements were used. Eleven out of the 44 patients (25%)
had positive MRD at the cut-off level of 10−3 (pB-ALL) or 10−2
(T-ALL); 10/39 (25.6%) pB-ALL patients and 1/5 (20%) T-ALL
patients. Eight out of the 11 had been assigned to the high-
risk group at diagnosis; two of them were BCR-ABL-positive
and another was MLL-AF4-positive. The observed sensitivity
of the assay with the speciﬁc primers varied from 10−3 to 10−5.
According to MRD RQ-PCR cut-off points established by the
GBTLI-2009 protocol, the agreement between the two  methods
using Kappa statistics was 40% for pB-ALL and 100% for T-
ALL. When a cut-off point of 1 × 10−2 was used for pB-ALL, the
Kappa coefﬁcient was 75%, and considering a cut-off point of
1 × 10−3 for T-ALL, it was 50% (Table 2). Most divergent results
between assays were patients with MRD loads between 10−2
and 10−3, which were positive in RQ-PCR but negative in con-
ventional PCR.
Analysis  of  outcomeThe estimated 3.5-year probabilities of OS and EFS were 73.6%
and 68.2%, respectively, while the estimated 3.5-year probabil-
ity of LFS was 72.3% (Figure 1).
conventional polymerase chain reaction (PCR) and
Conventional PCR Concordance (%)
ative Positive
1 3 75.0
5 1 16.7
9 0 100.0
0 1 100.0
1 0 0
3 0 0
 lymphoblastic leukemia.
 × 10−2 for T-ALL.
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Figure 1 – Kaplan–Meier survival curve estimates for (A) overall survival and (B) event-free survival of all patients (n = 74);
and (C) leukemia-free survival in 72 patients.
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Figure 2 – Leukemia-free survival of 57 children with acute
lymphoblastic leukemia according to minimal residual
disease based on qualitative polymerase chain reaction.
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Figure 3 – Leukemia-free survival according to minimal
residual disease based on real-time quantitative
polymerase chain reaction at the end of induction in 44
There was no signiﬁcant association between RQ-PCR MRDThe median time of LFS for children without relapse was
.0 years (1.1–4.5 years) from the date of morphological bone
arrow remission. The median time from remission to relapse
as 1.2 years (0.5–2.5 years). The 3.5-year LFS was signiﬁcantly
igher in qualitatively MRD-negative children (84.1 ± 5.6%)
hen compared to MRD-positive children (41.7 ± 17.3%; p-
alue = 0.004) (Figure 2). There was no signiﬁcant association
etween any other analyzed clinical or biological variables and
FS. Even different protocols had no impact on survival (data
ot shown).
LFS data analysis for qualitative MRD  results was repeated
onsidering only patients evaluated by both techniques,
ualitative PCR and RQ-PCR (n = 44). Again, qualitative
RD-negative patients had signiﬁcantly higher LFS than MRD-
ositive children (p-value = 0.032; Supplemental ﬁgure 1).children with acute lymphoblastic leukemia.
Cox’s regression model was used to assess the progno-
stic impact of qualitative MRD on LFS on Days 28–35. After
adjusting for the effect of gender, institution of origin, treat-
ment protocol, risk group, immunophenotype, WBC  count at
diagnosis and age in a multivariate analysis, MRD was the
only variable signiﬁcantly associated with LFS (p-value = 0.015)
(Table 3).
After excluding non-signiﬁcant variables, positive MRD  by
qualitative PCR on Days 28–35 was signiﬁcantly associated
with a lower LFS (p-value = 0.009). The relapse risk for posi-
tive MRD  patients on Days 28–35 was 4.6 higher than for those
with negative MRD (95% conﬁdence interval: 1.5–14.6).and LFS (Figure 3). Analyzing the individual data, only one
of six children (all with pB-ALL) with positive RQ-PCR MRD
378  rev bras hematol hemoter. 2 0 1 5;3  7(6):373–380
Table 3 – Cox model for the prognostic inﬂuence of minimal residual disease consensus primers on Days 28–35 on the
leukemia-free survival of 57 children with acute lymphoblastic leukemia.
Variable Degrees of freedom Coefﬁcient SE p-Value Estimated RR (95% CI)
Institution of origin 2 0.642
Protocol 2 0.621
Gender 1 −0.375 0.694 0.589 0.687 (0.176–2.678)
Risk group 1 0.550 1.090 0.614 1.733 (0.205–14.689)
Age group 1 −1.392 1.294 0.282 0.249 (0.020–3.138)
Immunophenotype 1 0.150 0.967 0.877 1.161 (0.175–7.725)
WBC at diagnosis 1 0.679 1.057 0.521 1.971 (0.248–15.643)
Qualitative MRD D28–35 1 2.762 1.138 0.015 15.827 (1.702–147.182)
SE: standard error; RR: relative risk; CI: conﬁdence interval; WBC: white blood cell count; MRD D28–35: minimal residual disease on Days 28–35.
Table 4 – Cox model for the prognostic inﬂuence of minimal residual disease based on real-time quantitative polymerase
chain reaction (RQ-PCR) on Days 28–35 on the leukemia-free survival of 44 children with acute lymphoblastic leukemia.
Variable Degrees of freedom Coefﬁcient SE p-Value Estimated RR (95% CI)
Institution of origin 2 0.974
Protocol 2 0.400
Gender 1 −0.730 0.733 0.319 0.482 (0.115–2.027)
Risk group 1 0.244 1.123 0.828 1.276 (0.141–11.530)
Age group 1 0.340 0.954 0.721 1.406 (0.217–9.110)
Immunophenotype 1 0.044 1.184 0.970 1.045 (0.103–10.647)
WBC at diagnosis 1 1.309 1.129 0.246 3.703 (0.405–33.873)
RQ-PCR MRD D28–35 1 0.689 0.867 0.427 1.993 (0.364–10.909)
te bloSE: standard error; RR: relative risk; CI: conﬁdence interval; WBC: whi
and negative qualitative MRD  relapsed so far, after one year of
remission. The remaining ﬁve are alive and without relapsing
for 3.2–4.0 years since the initial remission.
Cox’s regression model was used to determine the pro-
gnostic impact of RQ-PCR MRD  on Days 28–35 on LFS. After
adjusting for the effect of gender, institution of origin, treat-
ment protocol, risk group, WBC  count at diagnosis, age and
immunophenotype in a multivariate analysis, no variable was
statistically associated with LFS, including RQ-PCR MRD (p-
value = 0.427; Table 4).
Discussion
Risk stratiﬁcation is still a challenging issue in the treatment of
children with ALL. The stratiﬁcation of patients based on MRD
deﬁned by Ig/TCR markers using PCR at the end of induction
therapy was included in the Brazilian protocols for the ﬁrst
time in 2009 and is still under evaluation.20 The present study
aimed to compare a low-cost PCR-based technique of detec-
tion and monitoring MRD  with the gold standard method,
RQ-PCR.
The detection of at least one clonal rearrangement in 98.3%
of patients tested by PCR supports the applicability of the
GBTLI-2009 strategy for the screening of rearrangements in
the vast majority of children with ALL.
For pB-ALL patients, the prevalence of rearrangements
was similar to that found by van der Velden et al., Flohr
et al., and two other Brazilian studies using the same
methodology.9,13,21,22 The most common of the 19 clonal rear-
rangements screened was IgH,  followed by TCRD and IgK,
as observed by Thorn et al.23 In T-ALL, the most frequentod cell count; MRD D28–35: minimal residual disease on Days 28–35.
rearrangement was TCRG, in line with other studies.9,13,24
Frequency of the SIL-TAL1 rearrangement (18.2%) is also in
agreement with ﬁndings from other Brazilian groups.25
In the present study, two or more  clonal rearrangements
were detected in 87% of the pB-ALL and in 45% of the T-ALL
patients. Since most researchers propose two targets for MRD
monitoring,5 there is a need to increase T-ALL targets.
According to van der Velden, the sensitivity of the RQ-
PCR assay depends on several factors, including the type of
rearrangement.26 In this study, primers synthesized for IgH
and IgK rearrangements were the most sensitive and speciﬁc
as in previous reports,27 and should be the ﬁrst choice for MRD
monitoring in pB-ALL. The low speciﬁcity of TCRG rearrange-
ments (only two of the nine primers tested were approved in
the sensitivity and speciﬁcity tests) could be due to the size of
the N region,16 although this aspect was not evaluated in the
present study.
MRD by qualitative PCR was positive on Days 28–35 in
15.8% of the patients in this study, a ﬁgure within the range
described previously by Scrideli et al. using a similar method-
ology (13.2%).9 MRD by RQ-PCR was positive in 25% of the
patients at the end of induction.
Comparing the qualitative and quantitative techniques,
this study found a 40% agreement for pB-ALL and 100%
for T-ALL. All negative cases in the quantitative test were
also negative in the qualitative test. The GBTLI-2009 refer-
ence laboratory from Centro Infantil Boldrini (Campinas, SP,
Brazil) reported a 68% agreement between the two methods
for pB-ALL (n = 121) and 100% for T-ALL (n = 9) in an ongoing
prospective study (personal communication). The discordance
rate between the two assays for pB-ALL is not surprising since
the qualitative assay has low sensitivity (10−2 to 10−3) and
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herefore the qualitative test may miss pB-ALL patients char-
cterized as positive by the quantitative assay with a cut-off
oint of 10−3.
Several clinical trials that stratify patients based on RQ-PCR
RD  have shown that molecular response is highly predic-
ive for relapse in childhood ALL.28–30 In this study MRD by
ualitative PCR was the single variable that showed a sta-
istically signiﬁcant association with the LFS. Surprisingly,
Q-PCR MRD  showed no association, in contrast to what has
een observed in other studies.22,30 It is important to point
ut that the follow-up time of the present study is relatively
hort and patients who had been MRD-positive by RQ-PCR
ay relapse later on. Moreover, the number of patients eval-
ated was rather low. It is possible that the effect of low-level
RD on outcome detected by RQ-PCR would be evident had
 larger group of patients been studied. In addition, MRD
as studied at just one time point while other studies eval-
ated the kinetics of MRD  from the end of induction to
aintenance at two time points.6,28 The lack of association
etween RQ-PCR data and LFS in this study is intriguing and
eeds to be further examined in a larger cohort with a longer
ollow-up.
It is interesting to highlight that six pB-ALL patients with
 MRD  load close to 10−3 were identiﬁed as positive by RQ-
CR but negative by qualitative PCR. As already stated, only
ne patient has relapsed so far. Perhaps the sensitivity of the
ualitative assay may be enough to identify patients with a
elatively high-level MRD  who are at a higher risk of relapse
nd need intensiﬁcation of therapy or alternative protocols
hat could avoid relapse.
onclusions
he RQ-PCR method is highly sensitive and speciﬁc as reported
y many  institutions all over the world. The GBTLI-2009 proto-
ol also recommends this method for MRD  analysis in children
ith ALL. The present study, however, suggests that primer-
ased MRD  at the end of induction seems to be an effective
lternative to assign risk to children with ALL. Undoubtedly,
t is a simple and cost-effective strategy for institutions and
ountries with limited technical and ﬁnancial resources.
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